Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company whose news flow centers on glaucoma, corneal disorders, and retinal diseases. The company’s updates frequently highlight its Micro-Invasive Glaucoma Surgery (MIGS) platform, long-duration intracameral implants, and bio-activated pharmaceutical therapies for chronic eye conditions.
Investors following GKOS news can expect regular announcements on financial performance, including quarterly and annual net sales results, segment trends in glaucoma and corneal health, and updates to revenue guidance ranges. These disclosures are often accompanied by conference call and webcast details, as well as supplemental materials such as quarterly summary documents.
Product and pipeline developments are another major focus of Glaukos news. Recent communications have described the commercial launch activities for iDose TR, a long-duration intracameral procedural pharmaceutical implant for glaucoma, and U.S. FDA approval of Epioxa HD / Epioxa, an incision-free, epithelium-on corneal collagen cross-linking therapy for keratoconus. The company also highlights scientific presentations and posters featuring its technologies at major ophthalmology meetings.
Corporate and operational updates appear in the news flow as well, including participation in healthcare and investor conferences and plans for a new research, development, and manufacturing facility in Huntsville, Alabama. Together, these items provide insight into Glaukos’ commercial execution, research pipeline, manufacturing expansion, and overall strategy in ophthalmic pharmaceuticals and medical technology.
For market participants, the GKOS news page offers a consolidated view of these developments, making it easier to track key milestones in glaucoma devices, corneal cross-linking therapies, and other chronic eye disease initiatives reported by the company.
Glaukos (NYSE: GKOS) has announced its participation in two upcoming investor conferences: the William Blair 44th Annual Growth Stock Conference on June 5, 2024, at 1:40 p.m. ET in Chicago, and the Truist MedTech Conference on June 18, 2024, at 12:45 p.m. ET in Boston. Glaukos specializes in therapies for glaucoma, corneal disorders, and retinal diseases. Live and archived webcasts of these events will be available on the Glaukos website.
Glaukos (NYSE: GKOS) reported strong financial results for the first quarter of 2024, with record net sales of $85.6 million, marking a 16% increase year-over-year. The company raised its 2024 net sales guidance to $357 to $365 million. Glaukos continues to focus on developing innovative technologies to enhance patient care in ophthalmology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.